U.S. FDA Accepts Priority Review for Gilead’s Once-Daily HIV Therapy Combining Bictegravir and Lenacapavir
Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational once-daily, single-tablet regimen combining bictegravir 75 mg and lenacapavir 50 mg (BIC/LEN) for the treatment of HIV in virologically suppressed adults. The regulatory milestone marks an important step forward in the company’s ongoing efforts to advance innovative treatment options for people living with HIV, particularly those seeking simplified regimens with durable efficacy.
As part of the review process, the FDA has granted priority review status to the application, reflecting the potential of the therapy to address unmet medical needs or offer meaningful improvements over existing treatments. The agency has also assigned a target action date under the Prescription Drug User Fee Act (PDUFA) of August 27, 2026, by which it is expected to complete its evaluation of the submission.
The investigational BIC/LEN regimen combines two distinct antiretroviral agents with complementary mechanisms of action. Bictegravir, an integrase strand transfer inhibitor (INSTI), is known for its high barrier to resistance and strong antiviral potency. Lenacapavir, on the other hand, is a first-in-class capsid inhibitor that disrupts multiple stages of the HIV replication cycle. Importantly, lenacapavir’s novel mechanism does not exhibit cross-resistance with other classes of antiretroviral therapies, making it a potentially valuable option for patients with prior treatment experience or resistance concerns.
According to Dietmar Berger, the combination of these two agents could offer a differentiated treatment approach for people living with HIV. He emphasized that the regimen is designed to provide sustained virologic suppression while maintaining a high barrier to resistance. This is particularly relevant for individuals who are aging, managing comorbidities, or seeking to simplify complex multi-drug treatment regimens. Berger also noted that the therapy may benefit patients with prior antiretroviral resistance as well as those interested in exploring newer therapeutic options.
The NDA submission is supported by data from two pivotal Phase 3 clinical trials, ARTISTRY-1 and ARTISTRY-2, which evaluated the efficacy and safety of BIC/LEN in adults living with HIV who were already virologically suppressed. These studies included participants who transitioned from existing treatment regimens, including both complex multi-tablet therapies and established single-tablet regimens such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
Results from both trials demonstrated that BIC/LEN was comparable to existing therapies in maintaining virologic suppression through 48 weeks. This finding is critical, as maintaining suppression of the virus is the primary goal of HIV treatment, preventing disease progression and reducing the risk of transmission. In addition to efficacy, the regimen was generally well tolerated, with no significant or unexpected safety concerns identified during the studies.
The ARTISTRY-1 trial is particularly notable for enrolling the oldest population ever included in a Phase 3 registrational study for HIV treatment. This focus reflects the evolving demographics of the HIV population, as advances in therapy have enabled individuals to live longer, healthier lives. As a result, there is a growing need for treatment options that address the unique challenges faced by aging patients, including the management of comorbid conditions and the desire for simplified regimens.
Data presented at the Conference on Retroviruses and Opportunistic Infections 2026 (CROI 2026) highlighted additional benefits associated with switching to BIC/LEN from more complex regimens. Participants in the ARTISTRY-1 study experienced improvements in certain fasting lipid parameters, suggesting potential cardiovascular benefits. Additionally, patient-reported outcomes indicated higher levels of treatment satisfaction following the switch, underscoring the importance of convenience and tolerability in long-term HIV management.
The ARTISTRY-2 trial further supported the favorable profile of the regimen, demonstrating that switching to BIC/LEN did not result in significant changes in body weight. This is an important consideration, as weight gain has emerged as a concern with some antiretroviral therapies. Together, the findings from ARTISTRY-1 and ARTISTRY-2 provide a comprehensive assessment of the regimen’s performance across multiple clinical and patient-centered endpoints.
Detailed results from the ARTISTRY-1 study were published in The Lancet on March 28, 2026, further validating the scientific rigor and clinical relevance of the data. Publication in a leading peer-reviewed journal underscores the significance of the findings and their potential impact on clinical practice.
Jared Baeten, Senior Vice President of Clinical Development and Head of the Virology Therapeutic Area at Gilead Sciences, emphasized the company’s commitment to continuous innovation in HIV treatment. He noted that as patients remain on therapy for longer periods, their needs and preferences evolve, requiring new approaches that prioritize both efficacy and quality of life. Baeten highlighted that BIC/LEN, if approved, could complement Gilead’s existing portfolio, including Biktarvy, which remains a cornerstone of HIV treatment worldwide.
The development of BIC/LEN reflects broader trends in HIV care, where the focus is increasingly shifting toward regimen simplification, long-term tolerability, and personalization of therapy. While current treatments are highly effective, ongoing innovation is essential to address residual challenges such as adherence, drug resistance, and the management of comorbidities.
It is important to note that the combination of bictegravir and lenacapavir remains investigational and has not yet been approved for use in any country. The safety and efficacy of the regimen have not been fully established outside of clinical trials, and regulatory review is ongoing. As with all HIV therapies, continued research and evaluation will be necessary to confirm its long-term benefits and safety profile.
Despite significant advances in treatment, there is still no cure for HIV or AIDS. However, modern antiretroviral therapies have transformed the disease into a manageable chronic condition for many patients. Innovations such as BIC/LEN aim to further improve the treatment landscape by offering new options that align with the evolving needs of people living with HIV.
The FDA’s acceptance of Gilead’s NDA and the granting of priority review status represent a meaningful milestone in this journey. If approved, BIC/LEN could become an important addition to the arsenal of HIV therapies, providing a simplified, once-daily option with a high barrier to resistance and the potential to enhance long-term patient outcomes.
As the August 2026 PDUFA date approaches, the medical community will be closely watching the progress of this application. The outcome could have significant implications for the future of HIV treatment, reinforcing the role of innovation in addressing one of the world’s most persistent global health challenges.
About Biktarvy
Biktarvy is a complete HIV treatment that combines three powerful medicines to form the smallest 3-drug, integrase strand transfer inhibitor (INSTI)-based single-tablet regimen (STR) available, offering simple once-daily dosing with or without food, with a limited drug interaction potential and a high barrier to resistance. Biktarvy combines the novel, unboosted INSTI bictegravir, with the Descovy®(emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, F/TAF) backbone. Biktarvy is a complete STR and should not be taken with other HIV medicines.
About Bictegravir
Bictegravir is a global guideline-recommended integrase strand transfer inhibitor (INSTI) with a high barrier to resistance. INSTIs are a class of antiretroviral agents that target the viral integrase. Bictegravir is used only in combination with other antiretroviral agents in the treatment of HIV.
About Lenacapavir
Lenacapavir is approved in multiple countries for the treatment of multi-drug-resistant HIV in adults, in combination with other antiretrovirals. Lenacapavir is also approved in multiple countries as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents who are at risk of HIV acquisition.
The multi-stage mechanism of action of lenacapavir is distinguishable from other approved classes of antiretroviral agents. While most antiretrovirals act on one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known exhibited cross-resistance in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV treatment and prevention research program. Lenacapavir is being developed as a foundation for potential future HIV therapies to offer both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address the individual needs and preferences of people and communities affected by HIV.
Source Link:https://www.businesswire.com/
